Mirum Pharmaceuticals, Inc. (MIRM) Dividend History

Company News

• Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

  Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.

  Zacks Investment Research

  Featured Companies: ACRV ALGS RAPT
• Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

  Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  Zacks Investment Research

  Featured Companies: BMRN
• Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?

  Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research

  Featured Companies: AXSM
• Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns

  Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

  Zacks Investment Research

  Featured Companies: KRYS NERV
• Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

  Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.

  Zacks Investment Research

  Featured Companies: ENTX LGND THRD